KDM2B: A Critical Protein Regulating Gene Expression and Chromatin Structure

Target Name: KDM2B

NCBI ID: G84678

KDM2B

KDM2B: A Critical Protein Regulating Gene Expression and Chromatin Structure

Histone demethylation is a complex process that plays a crucial role in the regulation of gene expression and chromatin structure. Histone methylation is a post-translational modification that involves the addition of a methyl group to the histone alpha chains. This modification can either enhance or decrease gene expression, and is involved in a wide range of cellular processes, including cell growth, differentiation, and DNA replication.

One of the key proteins involved in histone demethylation is KDM2B (jmjC domain-containing histone demethylation protein 1B). KDM2B is a protein that was discovered in 2008 and is expressed in a wide range of tissues, including muscle, liver, and brain. The KDM2B protein is composed of 191 amino acid residues and has a calculated molecular mass of 21 kDa.

KDM2B is a histone demethylation enzyme that uses a unique mechanism of demethylation. It has a single domain, the jmjC domain, which is located at the N-terminus of the protein. The jmjC domain is composed of 119 amino acid residues and is responsible for the histone demethylation that occurs on the alpha chains.

KDM2B functions by binding to the alpha-2 chain of histone H3 and using a unique conformational change to remove the methyl group from this chain. This conformational change involves a significant change in the structure of the protein, allowing KDM2B to access the methyl group on the alpha-2 chain. Once the methyl group is removed, the alpha-2 chain is then available for modification by other enzymes, such as histone acetylases.

KDM2B is a critical protein for the regulation of gene expression and chromatin structure. It is involved in the demethylation of the alpha-2 chain of histone H3, which is critical for the regulation of gene expression. KDM2B is also involved in the regulation of DNA replication, and has been shown to be involved in the regulation of the growth and differentiation of various tissues.

In addition to its role in gene expression and DNA replication, KDM2B is also a potential drug target. The jmjC domain of KDM2B is a unique structure that makes it a potential target for small molecules. Several studies have shown that the jmjC domain of KDM2B is sensitive to small molecules, and that the use of these molecules can inhibit the activity of KDM2B.

Furthermore, KDM2B has also been shown to play a role in the regulation of inflammation. The KDM2B gene is highly expressed in a variety of tissues that are involved in inflammation, including muscle, liver, and brain. Therefore, KDM2B has been shown to be involved in the regulation of inflammation and may be a potential biomarker for this disease.

In conclusion, KDM2B is a protein that plays a critical role in the regulation of gene expression and chromatin structure. It is involved in the demethylation of the alpha-2 chain of histone H3 and is a potential drug target. Further research is needed to fully understand the role of KDM2B in the regulation of gene expression and chromatin structure, as well as its potential as a drug target and biomarker.

Protein Name: Lysine Demethylase 2B

Functions: Histone demethylase that demethylates 'Lys-4' and 'Lys-36' of histone H3, thereby playing a central role in histone code (PubMed:16362057, PubMed:17994099, PubMed:26237645). Preferentially demethylates trimethylated H3 'Lys-4' and dimethylated H3 'Lys-36' residue while it has weak or no activity for mono- and tri-methylated H3 'Lys-36' (PubMed:16362057, PubMed:17994099, PubMed:26237645). Preferentially binds the transcribed region of ribosomal RNA and represses the transcription of ribosomal RNA genes which inhibits cell growth and proliferation (PubMed:16362057, PubMed:17994099). May also serve as a substrate-recognition component of the SCF (SKP1-CUL1-F-box protein)-type E3 ubiquitin ligase complex (Probable)

The "KDM2B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KDM2B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets